Cytosolic DNA Sensing in Organismal Tumor Control

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

A Toll-like receptor recognizes bacterial DNA

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056

Cellular senescence: from physiology to pathology

Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

Molecular mechanisms of cisplatin resistance

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111

Autophagy in major human diseases

Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585

Immunogenic cell stress and death

Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, É., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,210

Detection of immunogenic cell death and its relevance for cancer therapy

Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138

Mitochondrial control of inflammation

Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027

The hallmarks of cancer immune evasion

Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

McBride, S., Sherman, E., Tsai, C. J., Baxi, S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D., Michel, L. S., Young, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00290 · Cited by 402

Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity

Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00674-x · Cited by 435

Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology · doi:10.1038/s41590-019-0561-4 · Cited by 385

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy

Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 372

Mutant p53 Suppresses Innate Immune Signaling to Promote Tumorigenesis

Ghosh, M., Saha, S., Bettke, J. A., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 355

Cancer cell metabolism and antitumour immunity

Martino, M. D., Rathmell, J. C., Galluzzi, L., & Vanpouille‐Box, C. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 385

Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy

Zheng, J., Mo, J., Zhu, T., Zhuo, W., Yi, Y., Hu, S., Yin, J., Zhang, W., Zhou, H., & Liu, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01250-1 · Cited by 344

Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity

Schadt, L., Sparano, C., Schweiger, N. A., Siliņa, K., Cecconi, V., Lucchiari, G., Yagita∥, H., Guggisberg, E., Saba, S., Naščáková, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.065 · Cited by 299

Trial watch: STING agonists in cancer therapy

Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289

Trial watch: TLR3 agonists in cancer therapy

Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239

Mitophagy in tumorigenesis and metastasis

Poole, L. P., & Macleod, K. F. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03774-1 · Cited by 257

Lysine catabolism reprograms tumour immunity through histone crotonylation

Yuan, H., Wu, X., Wu, Q., Chatoff, A. G., Megill, E., Gao, J., Huang, T., Duan, T., Yang, K., Jin, C., et al. (2023) · Nature · doi:10.1038/s41586-023-06061-0 · Cited by 250

Targeting innate immune pathways for cancer immunotherapy

Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 234

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212

Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy

Deutsch, É., Chargari, C., Galluzzi, L., & Kroemer, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30171-8 · Cited by 216

Senolytics and senostatics as adjuvant tumour therapy

Short, S. C., Fielder, E., Miwa, S., & von Zglinicki, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.056 · Cited by 207

The two sides of chromosomal instability: drivers and brakes in cancer

Hosea, R., Hillary, S., Naqvi, S., Wu, S., & Kasim, V. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01767-7 · Cited by 226

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Reisländer, T., Lombardi, E. P., Groelly, F. J., Miar, A., Porru, M., Vito, S. D., Wright, B., Lockstone, H. E., Biroccio, A., Harris, A. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11048-5 · Cited by 197

NK cells and solid tumors: therapeutic potential and persisting obstacles

Tong, L., Jiménez‐Cortegana, C., Tay, A. H. M., Wickström, S. L., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 197

Trial watch: IDO inhibitors in cancer therapy

Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 195

Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles

Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162

Revisiting the Radiobiology of Targeted Alpha Therapy

Pouget, J., & Constanzo, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.692436 · Cited by 157

Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients

Rodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147

Trial watch: dendritic cell vaccination for cancer immunotherapy

Sprooten, J., Ceusters, J., Coosemans, A., Agostinis, P., Vleeschouwer, S. D., Zitvogel, L., Kroemer, G., Galluzzi, L., & Garg, A. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638212 · Cited by 151

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response

Kim, C., Wang, X.-D., & Yu, Y. (2020) · eLife · doi:10.7554/elife.60637 · Cited by 136

Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10

Mowat, C., Mosley, S. R., Namdar, A., Schiller, D., & Baker, K. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210108 · Cited by 129

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

Crisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 137

Type I interferon and cancer

Holíček, P., Guilbaud, E., Klapp, V., Truxová, I., Špíšek, R., Galluzzi, L., & Fucikova, J. P. (2023) · Immunological Reviews · doi:10.1111/imr.13272 · Cited by 143

Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?

Wirsdörfer, F., de Leve, S., & Jendrossek, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010024 · Cited by 133

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

Machete identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis

Barriga, F. M., Tsanov, K. M., Ho, Y.-J., Sohail, N., Zhang, A., Baslan, T., Wuest, A. N., Del Priore, I., Meškauskaitė, B., Livshits, G., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00443-5 · Cited by 125

Immunosurveillance in clinical cancer management

Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 131

The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer

Bercovici, N., Guérin, M. V., Trautmann, A., & Donnadieu, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01563 · Cited by 127

Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)

Mori, Y., Novruzov, E., Schmitt, D. R., Cardinale, J., Watabe, T., Choyke, P. L., Alavi, A. A., Haberkorn, U., & Giesel, F. L. (2024) · npj Imaging · doi:10.1038/s44303-024-00053-z · Cited by 129

Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker

Sharma, A., & Johnson, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29153 · Cited by 122

Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration

Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 117

FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells

Shen, J. Z., Qiu, Z., Wu, Q., Finlay, D., Garcia, G., Sun, D., Rantala, J., Barshop, W., Hope, J. L., Gimple, R. C., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.042 · Cited by 113

5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING

Tian, J., Zhang, D., Kurbatov, V., Wang, Q., Wang, Y., Fang, D., Wu, L., Bosenberg, M., Muzumdar, M. D., Khan, S. A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106065 · Cited by 114

The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING–IFN-β pathway

Takahashi, M., Lio, C. J., Campeau, A., Steger, M., Ay, F., Mann, M., Gonzalez, D. J., Jain, M., & Sharma, S. (2021) · Nature Immunology · doi:10.1038/s41590-021-00896-3 · Cited by 118

The DNA Damage Response and Inflammation in Cancer

Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 115

Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity

Guillon, J., Petit, C., Toutain, B., Guette, C., Lelièvre, E., & Coqueret, O. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1652047 · Cited by 102

Ribosome biogenesis restricts innate immune responses to virus infection and DNA

Bianco, C., & Mohr, I. (2019) · eLife · doi:10.7554/elife.49551 · Cited by 103

Interfaces between cellular responses to DNA damage and cancer immunotherapyPreprint

Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 96

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses

Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 96

Properties and Application of Cell-Free DNA as a Clinical Biomarker

de Miranda, F. S., Baraúna, V. G., dos Santos, L., Costa, G. G. D., Vassallo, P. F., & Campos, L. C. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179110 · Cited by 96

Extracorporeal photochemotherapy induces bona fide immunogenic cell death

Tatsuno, K., Yamazaki, T., Hanlon, D. J., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F. E., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1819-3 · Cited by 94

Type I interferons and endoplasmic reticulum stress in health and disease

(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83

cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging

Schmitz, C. R. R., Maurmann, R. M., Guma, F. T. C. R., Bauer, M. E., & Barbé‐Tuana, F. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132653 · Cited by 95

Manganese( ii ) complexes stimulate antitumor immunity via aggravating DNA damage and activating the cGAS-STING pathway

Cai, L., Wang, Y., Chen, Y., Chen, H., Yang, T., Zhang, S., Guo, Z., & Wang, X. (2023) · Chemical Science · doi:10.1039/d2sc06036a · Cited by 88

Immunogenicity of ferroptosis in cancer: a matter of context?

Catanzaro, E., Demuynck, R., Naessens, F., Galluzzi, L., & Krysko, D. V. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.013 · Cited by 87

Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity

Hou, Y., Liang, H. L., Yu, X., Liu, Z., Cao, X., Rao, E., Huang, X., Wang, L., Li, L., Bugno, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0130 · Cited by 85

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85

Harnessing radiation to improve immunotherapy: better with particles?

Durante, M., & Formenti, S. C. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190224 · Cited by 85

Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better

Thiruppathi, J., Vijayan, V., Park, I., Lee, S. E., & Rhee, J. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375767 · Cited by 85

The DNA-damage response and nuclear events as regulators of nonapoptotic forms of cell death

Prokhorova, E. A., Egorshina, A. Y., Zhivotovsky, B., & Kopeina, G. S. (2019) · Oncogene · doi:10.1038/s41388-019-0980-6 · Cited by 80

Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer

Sheehan, C. S., & D’Souza‐Schorey, C. (2019) · Journal of Cell Science · doi:10.1242/jcs.235085 · Cited by 79

DNA Damage and Activation of cGAS/STING Pathway Induce Tumor Microenvironment Remodeling

Shen, R., Liu, D., Wang, X., Guo, Z., Sun, H., Song, Y., & Wang, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.828657 · Cited by 77

Mitophagy and Mitochondrial Dysfunction in Cancer

Macleod, K. F. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033405 · Cited by 76

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

Ghiringhelli, F., & Fumet, J.-D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01816 · Cited by 78

Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?

Çetintaş, V. B., & Batada, N. N. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02219-w · Cited by 69

Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion

Tripathi, R., Modur, V., Senovilla, L., Kroemer, G., & Komurov, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657374 · Cited by 66

Autophagy and cancer cell metabolism

Anderson, C. M., & Macleod, K. F. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.06.002 · Cited by 63

Molecular determinants of immunogenic cell death elicited by radiation therapy

Galassi, C., Klapp, V., Yamazaki, T., & Galluzzi, L. (2023) · Immunological Reviews · doi:10.1111/imr.13271 · Cited by 65

Senescence under appraisal: hopes and challenges revisited

Davan-Wetton, C. S. A., Pessolano, E., Perretti, M., & Montero‐Melendez, T. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03746-x · Cited by 61

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

Truxova, I., Kasikova, L., Salek, C., Hensler, M., Lysak, D., Holicek, P., Bilkova, P., Holubova, M., Chen, X., Mikyskova, R., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.223933 · Cited by 56

TREX1 – Apex predator of cytosolic DNA metabolism

Simpson, S. R., Hemphill, W. O., Hudson, T., & Perrino, F. W. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102894 · Cited by 54

USP49 negatively regulates cellular antiviral responses via deconjugating K63-linked ubiquitination of MITA

Ye, L., Zhang, Q., Liuyu, T., Xu, Z., Zhang, M., Luo, M., Zeng, W., Zhu, Q., Lin, D., & Zhong, B. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007680 · Cited by 53

Exosomes as Powerful Engines in Cancer: Isolation, Characterization and Detection Techniques

Saad, M. G., Beyenal, H., & Dong, W. (2021) · Biosensors · doi:10.3390/bios11120518 · Cited by 52

The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy

Stagg, J., Golden, E. B., Wennerberg, E., & Demaria, S. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3015 · Cited by 54

Considerations for the delivery of STING ligands in cancer immunotherapy

Petrovic, M., Borchard, G., & Jordan, O. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.033 · Cited by 51

cGAS/STING: novel perspectives of the classic pathway

Gao, M., He, Y., Tang, H., Chen, X., Liu, S., & Tao, Y. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00006-z · Cited by 50

The cGAS/STING–TBK1–IRF Regulatory Axis Orchestrates a Primitive Interferon-Like Antiviral Mechanism in Oyster

Qiao, X., Zong, Y., Liu, Z., Wu, Z., Li, Y., Wang, L., & Song, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689783 · Cited by 47

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-Cell mediated anti-tumor immunity in an esophageal adenocarcinoma model

Zaidi, A. H., Kelly, R. J., Gorbunova, A., Omstead, A. N., Salvitti, M. S., Zheng, P., Kosovec, J. E., Lee, S., Ayazi, S., Babar, L., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27886 · Cited by 46

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis

Manetsch, P., Böhi, F., Nowak, K., Pedrioli, D. M. L., & Hottiger, M. O. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309047120 · Cited by 42

Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING

Wang, L., Luo, R., Onyshchenko, K., Rao, X., Wang, M., Menz, B., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006235 · Cited by 45

Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA

Murphy, L. C., Inchauspé, J., Valenzano, G., Holland, P. J., Sousos, N., Belnoue-Davis, H. L., Li, R., Jooss, N. J., Benlabiod, C., Murphy, E., et al. (2025) · Science · doi:10.1126/science.adp3971 · Cited by 43

Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour

Jeong, S., Yang, M. J., Choi, S., Kim, J., & Koh, G. Y. (2021) · Nature Communications · doi:10.1038/s41467-021-24603-w · Cited by 46

Current strategies employed in the manipulation of gene expression for clinical purposes

Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 48

Record‐High Ultrasound‐Sensitive NO Nanogenerators for Cascade Tumor Pyroptosis and Immunotherapy

Bao, Y., Ge, Y., Wu, M., Mao, Z., Ye, J., & Tong, W. (2023) · Advanced Science · doi:10.1002/advs.202302278 · Cited by 41

A next-generation STING agonist MSA-2: From mechanism to application

Yang, J., Luo, Z., Ma, J., Wang, Y., & Cheng, N. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.042 · Cited by 41

DNA Associated with Circulating Exosomes as a Biomarker for Glioma

Vaidya, M., & Sugaya, K. (2020) · Genes · doi:10.3390/genes11111276 · Cited by 41

Combined analysis and validation for DNA methylation and gene expression profiles associated with prostate cancer

Tong, Y., Song, Y., & Deng, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0753-x · Cited by 37

The primitive interferon-like system and its antiviral function in molluscs

Qiao, X., Wang, L., & Song, L. (2021) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2021.103997 · Cited by 39

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 39

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma

Schiantarelli, J., Benamar, M., Park, J., Sax, H. E., Oliveira, G., Bosma-Moody, A., Campbell, K. M., Liu, D., Johnson, D. B., Rodig, S. J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.009 · Cited by 36

Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation

Goedegebuure, R. S. A., Kleibeuker, E. A., Buffa, F. M., Castricum, K. C. M., Haider, S. A., Schulkens, I. A. E., Kroode, L. T., van den Berg, J., Jacobs, M., van Berkel, A. M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01962-2 · Cited by 38

New insights into nucleic acid sensor AIM2: The potential benefit in targeted therapy for cancer

Cui, J.-Z., Chew, Z. H., & Lim, L. H. K. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107079 · Cited by 36

The cGAS-STING Pathway in Hematopoiesis and Its Physiopathological Significance

Liao, W., Du, C., & Wang, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573915 · Cited by 34

Detection and quantification of cytosolic DNA

Spada, S., Yamazaki, T., & Vanpouille‐Box, C. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.07.042 · Cited by 13

Sensing the Breaks: Cytosolic Chromatin in Senescence and Cancer

Micco, R. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.009 · Cited by 12

Negative Regulation of Cytosolic Sensing of DNA

Abe, T., & Shapira, S. D. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.09.002 · Cited by 29

Cloning and Characterization of Cytosolic DNA in Tumors

Yujia, S., & Stephan, G. (2013) · Frontiers in Immunology · doi:10.3389/conf.fimmu.2013.02.00436

DNA sensing and immune responses in cancer therapy

Qiao, J., Tang, H., & Fu, Y. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.12.005 · Cited by 17